vs
Side-by-side financial comparison of DT Cloud Star Acquisition Corp (DTSQ) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
Scinai Immunotherapeutics Ltd. is the larger business by last-quarter revenue ($773.0K vs $452.4K, roughly 1.7× DT Cloud Star Acquisition Corp).
DT Cloud Star Acquisition Corp is a special purpose acquisition company dedicated to pursuing business combinations with high-growth enterprises operating in cloud technology, enterprise software and digital services sectors, primarily targeting innovative players across the Asia-Pacific region.
DTSQ vs SCNI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $452.4K | $773.0K |
| Net Profit | $288.0K | — |
| Gross Margin | — | — |
| Operating Margin | -36.4% | — |
| Net Margin | 63.7% | — |
| Revenue YoY | — | 172.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $452.4K | — | ||
| Q3 25 | $751.5K | — | ||
| Q2 25 | $742.2K | $773.0K | ||
| Q1 25 | $737.7K | — | ||
| Q2 24 | — | $284.0K |
| Q4 25 | $288.0K | — | ||
| Q3 25 | $583.0K | — | ||
| Q2 25 | $631.5K | — | ||
| Q1 25 | $630.3K | — | ||
| Q2 24 | — | — |
| Q4 25 | -36.4% | — | ||
| Q3 25 | -22.5% | — | ||
| Q2 25 | -15.2% | — | ||
| Q1 25 | -15.0% | — | ||
| Q2 24 | — | — |
| Q4 25 | 63.7% | — | ||
| Q3 25 | 77.6% | — | ||
| Q2 25 | 85.1% | — | ||
| Q1 25 | 85.4% | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $461 | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-1.1M | $7.9M |
| Total Assets | $18.0M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $461 | — | ||
| Q3 25 | $20.1K | — | ||
| Q2 25 | $126.1K | $989.0K | ||
| Q1 25 | $271.5K | — | ||
| Q2 24 | — | $3.1M |
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-736.8K | — | ||
| Q2 25 | $-568.4K | $7.9M | ||
| Q1 25 | $-457.7K | — | ||
| Q2 24 | — | $-7.3M |
| Q4 25 | $18.0M | — | ||
| Q3 25 | $72.7M | — | ||
| Q2 25 | $72.1M | $11.8M | ||
| Q1 25 | $71.6M | — | ||
| Q2 24 | — | $14.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-411.0K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-411.0K | — | ||
| Q3 25 | $-105.9K | — | ||
| Q2 25 | $-145.5K | — | ||
| Q1 25 | $-139.9K | — | ||
| Q2 24 | — | — |
| Q4 25 | -1.43× | — | ||
| Q3 25 | -0.18× | — | ||
| Q2 25 | -0.23× | — | ||
| Q1 25 | -0.22× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
